CD19/CD22 tandem CAR constructs were administered to 12 patients with R/R B-ALL: 11 achieved a CR and 1 experienced primary progressive disease with CD19 retention [44]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.